"Reconsidering Beta-Blockers After Heart Attack: Insights from REDUCE-AMI Trial"
The REDUCE-AMI trial investigated the use of beta-blockers post-myocardial infarction (MI) in patients with preserved left ventricular ejection fraction and found no significant difference in the primary endpoint of death or MI between the beta-blocker and control groups. The trial's pragmatic nature and the changing landscape of MI care, with the widespread use of revascularization and modern therapies, raise questions about the relevance of beta-blockers in current post-MI care. The results challenge the long-standing dogma of beta-blocker use after MI and emphasize the importance of retesting old treatment paradigms, while ongoing trials may provide further insights into the role of beta-blockade in post-MI care.